A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Major Depressive Disorder
Latest Information Update: 30 Jan 2025
Price :
$35 *
At a glance
- Drugs ONO 1110 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 30 Jan 2025 New trial record